APP:NASDAQApplovin Corporation Analysis
Data as of 2026-05-28 - not real-time
$567.83
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
AppLovin delivered a blockbuster Q1 2026 with revenue of $1.84 B, up 59% YoY and beating the consensus $1.77 B estimate. Adjusted EPS surged, sending the stock 3% higher after the release. The company’s margins remain extraordinary—gross margin ~88%, operating margin ~78% and profit margin ~64%—supporting robust cash generation. Technicals are also supportive: the price of $567 sits above the 20‑day and 50‑day SMAs, the MACD is bullish, and RSI at 68.7 signals strong momentum, though it approaches overbought territory. However, valuation metrics are extreme, with a trailing PE of 49 versus an industry average of 17 and a price‑to‑book of over 80, placing the current price well above the DCF‑derived fair value of $337.
Balance‑sheet leverage and volatility temper the optimism: debt‑to‑equity exceeds 160% and ROE is modest at 2.7%, while a beta of 2.24 and 30‑day volatility near 66% indicate high sensitivity to market swings. The “Extreme Greed” sentiment index suggests a potentially crowded trade. Despite these risks, analysts maintain a strong‑buy consensus with an upside potential of about 13‑15% toward the median target of $660, bolstered by an upcoming product milestone in June. Investors must weigh the compelling growth against the pronounced valuation premium and volatility.
Balance‑sheet leverage and volatility temper the optimism: debt‑to‑equity exceeds 160% and ROE is modest at 2.7%, while a beta of 2.24 and 30‑day volatility near 66% indicate high sensitivity to market swings. The “Extreme Greed” sentiment index suggests a potentially crowded trade. Despite these risks, analysts maintain a strong‑buy consensus with an upside potential of about 13‑15% toward the median target of $660, bolstered by an upcoming product milestone in June. Investors must weigh the compelling growth against the pronounced valuation premium and volatility.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Quarterly earnings beat and accelerating revenue growth
- Bullish technical setup (price above SMAs, MACD bullish)
- High short‑term momentum despite overbought RSI
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained double‑digit revenue growth and expanding margins
- Upcoming product milestone expected to deepen platform stickiness
- Analyst consensus strong‑buy with median target above current price
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Valuation remains far above fundamentals (PE, PB, DCF)
- Elevated leverage and modest ROE raise capital efficiency concerns
- High beta and volatility could amplify market downturn impacts
Key Metrics & Analysis
Financial Health
Revenue Growth59.00%
Profit Margin64.29%
P/E Ratio49.2
ROE266.44%
ROA44.24%
Debt/Equity162.89
P/B Ratio80.8
Op. Cash Flow$4.4B
Free Cash Flow$3.2B
Industry P/E17.1
Technical Analysis
TrendNeutral
RSI68.7
Support$430.25
Resistance$581.00
MA 20$482.46
MA 50$451.69
MA 200$534.97
MACDBullish
VolumeStable
Fear & Greed Index91.54
Valuation
Fair Value$337.11
Target Price$644.47
Upside/Downside13.50%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.24
Volatility65.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.